Figure 2

AP2M1 is related to the poor prognosis of AML patients. A) Kaplan‐Meier curve stratified by expression level of AP2M1 from the TCGA dataset. The low, mid, and high groups included patients with transcriptional levels less than the first quartile, between the first and third quartiles, and higher than the third quartile, respectively. B) Cell types identified on UMAP projections from the bone marrow scRNA‐seq data of AML patients. C) The proportions of cell types and cell states. The first and second bar graphs represent the proportions of cell types and cell states in healthy individuals and AML patients. The third describes the proportions of cell types within each cell state. D) Comparison of AP2M1 expression levels between normal and malignant cells. The expression levels were compared between all cells and specifically within the five cell types with malignant states, HSPC, GMP, ProMono, Mono, and cDC. ^*p < .05, ^**p < 0.01, ^***p < .001. E) Proportion of AP2M1‐expressing cells according to cell states within the five cell types based on scRNA‐seq data. F) The mRNA level of AP2M1 was quantified in clinical samples. Samples were categorized into two groups, each comprising 10 individuals. qPCR was employed to measure the mRNA levels of AP2M1.